These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35860905)

  • 21. Inhibition of hedgehog and androgen receptor signaling pathways produced synergistic suppression of castration-resistant prostate cancer progression.
    Gowda PS; Deng JD; Mishra S; Bandyopadhyay A; Liang S; Lin S; Mahalingam D; Sun LZ
    Mol Cancer Res; 2013 Nov; 11(11):1448-61. PubMed ID: 23989930
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-androgen therapy induces transcriptomic reprogramming in metastatic castration-resistant prostate cancer in a murine model.
    Zhao Y; Peng X; Baldwin H; Zhang C; Liu Z; Lu X
    Biochim Biophys Acta Mol Basis Dis; 2021 Jul; 1867(7):166151. PubMed ID: 33892077
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patient-derived Hormone-naive Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer.
    Hao J; Ci X; Xue H; Wu R; Dong X; Choi SYC; He H; Wang Y; Zhang F; Qu S; Zhang F; Haegert AM; Gout PW; Zoubeidi A; Collins C; Gleave ME; Lin D; Wang Y
    Eur Urol; 2018 Jun; 73(6):949-960. PubMed ID: 29544736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural killer cells suppress enzalutamide resistance and cell invasion in the castration resistant prostate cancer via targeting the androgen receptor splicing variant 7 (ARv7).
    Lin SJ; Chou FJ; Li L; Lin CY; Yeh S; Chang C
    Cancer Lett; 2017 Jul; 398():62-69. PubMed ID: 28373004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.
    Guan W; Hu J; Yang L; Tan P; Tang Z; West BL; Bollag G; Xu H; Wu L
    Endocr Relat Cancer; 2019 Jan; 26(1):131-140. PubMed ID: 30400004
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Agent-based modeling of the prostate tumor microenvironment uncovers spatial tumor growth constraints and immunomodulatory properties.
    van Genderen MNG; Kneppers J; Zaalberg A; Bekers EM; Bergman AM; Zwart W; Eduati F
    NPJ Syst Biol Appl; 2024 Feb; 10(1):20. PubMed ID: 38383542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mediator kinase inhibition reverses castration resistance of advanced prostate cancer.
    Li J; Hilimire TA; Liu Y; Wang L; Liang J; Gyorffy B; Sikirzhytski V; Ji H; Zhang L; Cheng C; Ding X; Kerr KR; Dowling CE; Chumanevich AA; Mack ZT; Schools GP; Lim CU; Ellis L; Zi X; Porter DC; Broude EV; McInnes C; Wilding G; Lilly MB; Roninson IB; Chen M
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38546787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the MIF/CXCR7/AKT Signaling Pathway in Castration-Resistant Prostate Cancer.
    Rafiei S; Gui B; Wu J; Liu XS; Kibel AS; Jia L
    Mol Cancer Res; 2019 Jan; 17(1):263-276. PubMed ID: 30224544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. GATA2 promotes castration-resistant prostate cancer development by suppressing IFN-β axis-mediated antitumor immunity.
    Jin Z; Wang H; Tang R; Pan B; Lee HJ; Liu S; Wang L; Qin J; Xu M
    Oncogene; 2024 Aug; 43(34):2595-2610. PubMed ID: 39068217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Androgens modify therapeutic response to cabazitaxel in models of advanced prostate cancer.
    Begemann D; Wang Y; Yang W; Kyprianou N
    Prostate; 2020 Sep; 80(12):926-937. PubMed ID: 32542812
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RGS2 is prognostic for development of castration resistance and cancer-specific survival in castration-resistant prostate cancer.
    Linder A; Larsson K; Welén K; Damber JE
    Prostate; 2020 Aug; 80(11):799-810. PubMed ID: 32449815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-derived OBP2A promotes prostate cancer castration resistance.
    Jeong JH; Zhong S; Li F; Huang C; Chen X; Liu Q; Peng S; Park H; Lee YM; Dhillon J; Luo JL
    J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36547668
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.
    Karantanos T; Evans CP; Tombal B; Thompson TC; Montironi R; Isaacs WB
    Eur Urol; 2015 Mar; 67(3):470-9. PubMed ID: 25306226
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [COST ANALYSIS OF ANDROGEN DEPRIVATION THERAPY AND DRUGS FOR CASTRATION-RESISTANT PROSTATE CANCER].
    Nishizawa K; Hattahara K; Onishi H; Yoshida T
    Nihon Hinyokika Gakkai Zasshi; 2021; 112(2):53-57. PubMed ID: 35444081
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
    Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
    EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current Treatment Modalities Targeting Tumor Microenvironment in Castration-Resistant Prostate Cancer.
    Nagireddy S; Qureshi R; Best J; Frech FS; Shah K; Soni Y; Kuchakulla M; Narasimman M; Arora H
    Adv Exp Med Biol; 2021; 1329():295-323. PubMed ID: 34664246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MicroRNA Regulation of Androgen Receptor in Castration-Resistant Prostate Cancer: Premises, Promises, and Potentials.
    Ebrahimi S; Hashemy SI; Sahebkar A; Aghaee Bakhtiari SH
    Curr Mol Pharmacol; 2021 Oct; 14(4):559-569. PubMed ID: 33357209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CYP1B1-catalyzed 4-OHE2 promotes the castration resistance of prostate cancer stem cells by estrogen receptor α-mediated IL6 activation.
    Lin Q; Cao J; Du X; Yang K; Yang X; Liang Z; Shi J; Zhang J
    Cell Commun Signal; 2022 Mar; 20(1):31. PubMed ID: 35292057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Downregulation of
    Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
    Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NDRG2 acts as a negative regulator downstream of androgen receptor and inhibits the growth of androgen-dependent and castration-resistant prostate cancer.
    Yu C; Wu G; Li R; Gao L; Yang F; Zhao Y; Zhang J; Zhang R; Zhang J; Yao L; Yuan J; Li X
    Cancer Biol Ther; 2015; 16(2):287-96. PubMed ID: 25756511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.